6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Simultaneous quantitation of the BACE1 inhibitor AZD3293 and its metabolite AZ13569724 in human matrices by LC-MS/MS.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          AZD3293 is a novel BACE1 inhibitor in Phase III development for Alzheimer's disease. Sensitive and robust bioanalytical methods were required to quantitate AZD3293 and its metabolite AZ13569724 in human biological matrices.

          Related collections

          Author and article information

          Journal
          Bioanalysis
          Bioanalysis
          Future Science, LTD
          1757-6199
          1757-6180
          May 2017
          : 9
          : 10
          Affiliations
          [1 ] Early Clinical Development, IMED Biotech Unit, AstraZeneca, Waltham, MA, USA 02451.
          [2 ] Clinical Laboratories, Covance Laboratories, Inc., Madison, WI, USA 53704.
          [3 ] Drug Disposition, Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, IN, USA 46285.
          [4 ] Clinical Pharmacology, Coastal Pharma Group, Concord, MA, USA 01742.
          Article
          10.4155/bio-2017-0003
          28434245
          792c46be-2cad-4695-be61-07073ebfa263
          History

          AZD3293,BACE1,LC–MS/MS,PUF,cerebrospinal fluid,plasma,urine
          AZD3293, BACE1, LC–MS/MS, PUF, cerebrospinal fluid, plasma, urine

          Comments

          Comment on this article